학술논문

Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers
Document Type
Journal
Source
MOLECULAR CANCER THERAPEUTICS; DEC 2023, 22 12, 2p. Supplement: S
Subject
Language
English
ISSN
15388514